diaDexus, Inc. announced unaudited financial results for the fourth quarter and full year ended December 31, 2014. Total revenues for the fourth quarter of 2014 were $6.0 million, compared to $6.7 million reported in the fourth quarter of 2013. This decrease was primarily the result of the previously disclosed industry-wide impact from new, more restrictive guidance issued to cardiovascular testing facilities by the Office of the Inspector General in June 2014. The company's net loss for the fourth quarter 2014 was $2.3 million, or $0.04 per basic and diluted share, compared to a net loss of $0.2 million, or $0.00 per basic and diluted share, in the fourth quarter of 2013. Loss from operations was $1,927,000 against profit of $15,000 a year ago. Loss before income tax was $2,305,000 against $194,000 a year ago.

Total revenues for the full year 2014 were $26.4 million, compared to $24.9 million reported for 2013. This 6% increase was driven primarily by the Company's services provided under a 2014 agreement with GSK. The company's net loss for the full year 2014 was $8.5 million, or $0.15 per basic and diluted share, compared to a net loss of $2.2 million, or $0.04 per basic and diluted share, for 2013. Loss from operations was $6,982,000 against $2,015,000 a year ago. Loss before income tax was $8,452,000 against $2,159,000 a year ago. This 6% increase in revenue was driven by services they provided under a 2014 agreement with GSK.